Anne Cowppli-Bony1, Marc Colonna2, Karine Ligier3, Valérie Jooste4, Gautier Defossez5, Alain Monnereau6. 1. Registre des tumeurs de Loire-Atlantique et Vendée, 50, route de St-Sébastien, 44093 Nantes cedex 1, France; CHU de Nantes, SIRIC-ILIAD, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France; Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France. Electronic address: anne.cowpplibony@chu-nantes.fr. 2. Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; CHU de Grenoble, registre du cancer de l'Isère, pavillon E, CS 10217, 38043 Grenoble cedex 9, France. 3. Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; Conseil départemental du Pas-de-Calais, rue Ferdinand-Buisson, 62000 Arras, France. 4. Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; CHU de Dijon Bourgogne, registre bourguignon des cancers digestifs, 1, boulevard Jeanne-d'Arc, 21000 Dijon, France; Université de Bourgogne Franche Comté, UFR des sciences de santé, Inserm UMR 1231 « Lipides Nutrition Cancer », 7, boulevard Jeanne-d'Arc, 21079 Dijon cedex, France. 5. Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; CHU de Poitiers, université de Poitiers, registre général des cancers de Poitou-Charentes, rue de la Milétrie, TSA 51115, 86073 Poitiers cedex, France. 6. Université Paul-Sabatier, faculté de médecine, réseau des registres de cancers Francim, 37, allée Jules-Guesde, 31073 Toulouse cedex, France; Institut Bergonié, registre des hémopathies malignes de la Gironde, 229, cours de l'Argonne, 33000 Bordeaux, France; Université de Bordeaux, Inserm U1219, équipe EPICENE, ISPED, 146, rue Léo-Saignat, 33076 Bordeaux cedex, France.
Abstract
INTRODUCTION: Incidence, mortality, survival and prevalence are key indicators to assess public health policies and estimate the needs of the population for cancer management. The aim of this article is to provide the more current estimates of these indicators, in line with the fifteenth operational objective of the 2014-2019 Cancer Plan "Collect data/Support Public Health". METHODS: Incidence and survival data came from cancer registries. Mortality data came from the French epidemiology center on medical causes of death. Prevalence was estimated by using incidence and survival estimates. RESULTS: In metropolitan France in 2017, the estimated number of new cancer cases and cancer deaths was respectively 399,500 and 150,000. The most frequent cancers (breast, prostate) had highest net survivals: 78 and 84% at 10 years. Several cancers (including lung, liver and pancreatic cancers) had worse prognosis (5-year survival≤33%). In 2017, 1,396,000 men and 1,359,000 women had cancer in the previous 15 years, representing respectively 5.4% and 4.8% of the population aged 15 and over. DISCUSSION: Despite the decrease of cancer mortality, the prognosis of some cancers remains poor and the cancer prevalence is high. These results highlight the need for intensifying the efforts already made in cancer prevention, diagnosis, and treatment and justify the interest in the post-cancer period.
INTRODUCTION: Incidence, mortality, survival and prevalence are key indicators to assess public health policies and estimate the needs of the population for cancer management. The aim of this article is to provide the more current estimates of these indicators, in line with the fifteenth operational objective of the 2014-2019 Cancer Plan "Collect data/Support Public Health". METHODS: Incidence and survival data came from cancer registries. Mortality data came from the French epidemiology center on medical causes of death. Prevalence was estimated by using incidence and survival estimates. RESULTS: In metropolitan France in 2017, the estimated number of new cancer cases and cancer deaths was respectively 399,500 and 150,000. The most frequent cancers (breast, prostate) had highest net survivals: 78 and 84% at 10 years. Several cancers (including lung, liver and pancreatic cancers) had worse prognosis (5-year survival≤33%). In 2017, 1,396,000 men and 1,359,000 women had cancer in the previous 15 years, representing respectively 5.4% and 4.8% of the population aged 15 and over. DISCUSSION: Despite the decrease of cancer mortality, the prognosis of some cancers remains poor and the cancer prevalence is high. These results highlight the need for intensifying the efforts already made in cancer prevention, diagnosis, and treatment and justify the interest in the post-cancer period.
Authors: Jim Canet; Pascale Cony-Makhoul; Sébastien Orazio; Edouard Cornet; Xavier Troussard; Marc Maynadié; Gabriel Étienne; Alain Monnereau Journal: Cancer Med Date: 2021-09-22 Impact factor: 4.452